Bispecific Antibodies Market Trends & Growth 2020 | Global Industry Analysis By Size, Share, Revenue, Value, Technological Developments And Forecast To 2026

Bispecific antibodies (BsAb) are antibodies that can simultaneously bond two separate and unique antigens or different epitopes of the same antigens. Cancer immunotherapy is the most extensively explored application of bispecific antibody. Lung, breast, and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies are emerging a technologically advanced solution for dual targeting strategies within same molecule.

“We Do Offer Sample of this report. Kindly go through the follow information in order to access sample copy.”
Note- This report sample includes:
– Brief Introduction to the research report.
– Table of Contents (Scope covered as a part of the study)
– Top players in the market
– Research framework (structure of the report)
– Research methodology adopted by Coherent Market Insights

Request A Sample Copy – Bispecific Antibodies Market Report Click here: https://www.coherentmarketinsights.com/insight/request-sample/19

Due to its dual specificity, bispecific antibody can aid in redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites. Catumaxomab and blinatumomab are the two U.S. Food and Drug Administration (FDA) approved bispecific antibody products, which would fuel growth of the bispecific antibodies market. Bispecific antibodies can be divided into three main classes namely, fragment, symmetric, and asymmetric antibodies. Fragment bispecific antibodies such as a nanobody DART and BiTE are currently undergoing clinical trials. Likewise, tetravalent BsAb – DVD and DAF symmetric antibodies are under research. Companies such as Sanofi S.A., Merck & Co., Inc. and Genentech, Inc. are conducting research on symmetric bispecific antibodies. BEAT, duobody, and crossmab are examples of asymmetric bispecific antibodies, which are currently being researched by Glenmark Pharmaceuticals, Eli Lilly and Company, and Genmab A/S.

Market Dynamics- Drivers

Catumaxomab – the first Bispecific antibody boost growth of the bispecific antibodies market

Development of novel bispecific antibodies by market players is expected to drive growth of the global bispecific antibodies market during the forecast period. As of 2015, over 60 different BsAb formats have been developed, with some making their way into the clinical trials. Moreover, limitation of monoclonal antibodies in drug resistance and failure to respond in treatment is expected to drive the market growth in the near future.

Catumaxomab is a rat – mouse hybrid monoclonal bispecific trifunctional antibody used to treat malignant ascites. It was developed by Fresenius Biotech and Trion Pharma. Catumaxomab was approved in Europe in 2009 and is undergoing clinical trials in the U.S. Sold under the brand name Removab, Catumaxomab is administered to patients with EpCAM-poisitve carcinoma.

Regional Insights

North America and Europe are major regions for Bispecific antibodies market

Among regions, North America and Europe is expected to account for the significant market share during the forecast period. This is owing to growing incidence of diseases such as lung cancer, cervical cancer, breast cancer, and prostate cancer along with highest incidence rate for these diseases worldwide. Moreover, high presence of key players in the respective regions is expected to drive the market growth over the forecast period. Proactive government initiatives are further fueling growth of bispecific antibody treatment markets in North America and Europe. Emerging regions such as Asia Pacific, Latin America, and Middle East are projected witness significant growth, owing increasing healthcare access and awareness regarding BsAb in the region.

Increasing investments to harness the potential of highly effective BsAb Drug Therapy

Various pharmaceutical companies are actively involved in development and manufacture of bispecific antibodies. MedImmune, LLC and Abpro, collaborated in December 2016 to develop novel bispecific antibody, Ang2-VEGF, which targets angiopoietin-2 and vascular endothelial growth factor. Government funding is projected to further encourage research and development in this field.

Competitive Landscape

Major companies operating in the global bispecific antibodies market are Amgen, Inc., Bayer AG, Dow Pharmaceutical Solutions, ImmunGene, Inc., Immunocore Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and F. Hoffmann-La Roche AG.

Key Developments in the global bispecific antibodies market

The global bispecific antibodies market is expected to witness significant growth, owing to increasing research and development of novel bispecific antibodies. For instance, in January 2019, the Chinese Academy of Medical Sciences & Peking Union Medical College developed a new bispecific aptamer that enhances immune cytotoxicity against MUC1-positive tumor cells.

Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies, and more.
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/19

Moreover, in September 2018, researchers from China Pharmaceutical University constructed and expressed a fully human, bispecific, single-chain diabody that can bind to vascular endothelial growth factor 165 (VEGF165) and programmed death-1 in Pichia pastoris.

In August 2018, UCB Pharma, a scientific research company based in Belgium, conducted research on the molecular factors in bispecific antibody multimerisation and revealed that the monomer level of single-chain variable fragment-containing bispecific antibody formats can be increased by conversion of the single-chain variable fragment to a disulfide-stabilized single-chain variable fragment.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.